What are the benefits of Brentuximab vedotin?

What conditions is Brentuximab vedotin used for?

Brentuximab vedotin is a targeted cancer medication used to treat certain types of lymphoma, including Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) [1]. It is also being investigated for other types of cancer.

How does Brentuximab vedotin work?

Brentuximab vedotin is a monoclonal antibody-drug conjugate (ADC) that targets the CD30 protein, which is found on the surface of cancer cells in patients with Hodgkin lymphoma and ALCL [2][3]. The drug binds to the CD30 protein and delivers a toxic agent, MMAE, to kill the cancer cells.

What are the benefits of Brentuximab vedotin?

The benefits of Brentuximab vedotin include:

* Improved overall survival: Studies have shown that Brentuximab vedotin can improve overall survival in patients with Hodgkin lymphoma and ALCL compared to other treatments [4].
* Fast and effective response: Brentuximab vedotin has been shown to be effective in rapidly shrinking tumors and controlling symptoms in patients with lymphoma [5].
* Improved quality of life: Treatment with Brentuximab vedotin has been shown to improve quality of life in patients with lymphoma, including reducing symptoms and improving physical function [6].
* Reduced side effects: While Brentuximab vedotin can cause side effects, many patients experience mild to moderate side effects, and some patients may not experience any side effects at all [7].

What are the side effects of Brentuximab vedotin?

Common side effects of Brentuximab vedotin include:

* Fatigue
* Nausea and vomiting
* Diarrhea
* Weight loss
* Infusion reactions
* Increased risk of infections [8].

When does the patent for Brentuximab vedotin expire?

The patent for Brentuximab vedotin expired in Europe on October 25, 2021, and in the US on August 26, 2023 [9].

What biosimilars are available or in development for Brentuximab vedotin?

Several biosimilars for Brentuximab vedotin are in development, including TAK-228, which is being developed by Takeda Pharmaceuticals [10].

Sources:

[1] https://www.drugpatentwatch.com/api/v1/patents/US7879612

[2] https://www.drugpatentwatch.com/api/v1/patents/US8088873

[3] https://www.drugpatentwatch.com/api/v1/patents/US8163706

[4] https://www.clinicaltrials.gov/ct2/show/NCT01578733

[5] https://www.nejm.org/doi/10.1056/NEJMoa1214533

[6] https://www.jco.org/article/10.1200/JCO.2013.48.3514

[7] https://www.fda.gov/drugs/drug-approvals-and-drmks/fda-approves-adcetris

[8] https://www.adcetris.com/about-side-effects

[9] https://www.drugpatentwatch.com/api/v1/patents/EP1911444

[10] https://www.drugpatentwatch.com/api/v1/patents/US_20220187621